Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ORMP
$3.46
$
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Next Earnings
2026-02-25
Beta
1.308
Average Volume
Market Cap
Last Dividend
CIK
0001176309
ISIN
US68403P2039
CUSIP
68403P203
CEO
Nadav Kidron
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
13
IPO Date
2007-05-01
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above 50 Day Moving Average – Here’s Why | Oramed Pharmaceuticals Inc. (NASDAQ: ORMP - Get Free Report)'s stock price passed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.26 and traded as high as $3.35. Oramed Pharmaceuticals shares last traded at $3.31, with a volume of 368,355 shares trading hands. Wall Street Analyst Weigh | Defense World | 2026-02-24 04:56:55 |
| Comparing QuidelOrtho (NASDAQ:QDEL) & Oramed Pharmaceuticals (NASDAQ:ORMP) | QuidelOrtho (NASDAQ: QDEL - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings. Profitability This table compares QuidelOrtho and Oramed Pharmaceuticals' | Defense World | 2026-02-13 02:08:50 |
| Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above Fifty Day Moving Average – Time to Sell? | Oramed Pharmaceuticals Inc. (NASDAQ: ORMP - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.03 and traded as high as $3.60. Oramed Pharmaceuticals shares last traded at $3.59, with a volume of 436,246 shares trading hands. Wall Street Analyst Weigh | Defense World | 2026-01-27 04:58:51 |
| Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company | Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intended to provide Lifeward cash runway to profitability and diversify its portfolio across MedTech and BioTech Lifeward acquires Oramed's clinical-stage Protein Oral Delivery (POD™) technology adding exposure to a large, long-term Biotech market opportunity POD™ targets the $600+ billion injectable drugs market, including ORMD-0801, which has the potential to become the world's first commercialized oral insulin medicine MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. | GlobeNewsWire | 2026-01-13 08:00:00 |
| Oramed and Lifeward Announce Strategic Transaction | Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward while retaining management of clinical program Oramed will receive 49.9% beneficial ownership interest in Lifeward, a revenue-generating medical robotics company, including warrants Mark Grant, Lifeward CEO, with 25+ years experience in the diabetes sector at Medtronic and Bristol Myers Squibb, to lead combined platforms In addition, strategic investment by Oramed designed to bring Lifeward towards profitability Lifeward's FDA-approved ReWalk® and AlterG® products generated $26 million in last four quarters NEW YORK, Jan. 13, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed") and Lifeward Ltd. (NASDAQ: LFWD) ("Lifeward") today announced the signing of binding agreements for a strategic transaction between Oramed, Lifeward and a certain accredited investor. | PRNewsWire | 2026-01-13 07:58:00 |
| Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments | Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) today announced it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. This payment brings Oramed's current returns to $118 million on its original $99.5 million Scilex investment, with additional returns expected from the remaining convertible notes, warrants, and royalties. | PRNewsWire | 2026-01-07 08:55:00 |
| Reviewing Oramed Pharmaceuticals (NASDAQ:ORMP) & GE HealthCare Technologies (NASDAQ:GEHC) | Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) and GE HealthCare Technologies (NASDAQ: GEHC - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings. Risk and Volatility Oramed Pharmaceuticals has a | Defense World | 2026-01-04 05:22:51 |
| Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback | Oramed remains viable after its flagship product failed FDA trials three years ago. Management identified a responsive patient subset—elderly with low BMI and high baseline HbA1c—prompting a new 60-patient trial. Positive results from ORMP's Chinese partner reinforce the potential for this narrower patient group. | Seeking Alpha | 2025-12-24 14:28:51 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-20 | 2026-02-20 | View Filing |
| SC 13D/A | 2026-02-19 | 2026-02-19 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13G/A | 2026-02-09 | 2026-02-09 | View Filing |
| SC 13D | 2026-01-29 | 2026-01-29 | View Filing |
| 4 | 2026-01-29 | 2026-01-29 | View Filing |
| 4 | 2026-01-29 | 2026-01-29 | View Filing |
| 4 | 2026-01-29 | 2026-01-29 | View Filing |
| 4 | 2026-01-29 | 2026-01-29 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 8-K | 2026-01-14 | 2026-01-14 | View Filing |
| 8-K | 2026-01-07 | 2026-01-07 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2026-01-02 | 2026-01-02 | View Filing |
| 4 | 2026-01-02 | 2026-01-02 | View Filing |
| 8-K | 2025-12-31 | 2025-12-31 | View Filing |
| 8-K | 2025-12-31 | 2025-12-30 | View Filing |
| 8-K | 2025-11-17 | 2025-11-17 | View Filing |
| 8-A12B | 2025-11-17 | 2025-11-17 | View Filing |
| 8-K | 2025-11-17 | 2025-11-17 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-10-24 | 2025-10-23 | View Filing |
| 8-K | 2025-10-06 | 2025-10-06 | View Filing |
| SC 13D/A | 2025-08-28 | 2025-08-28 | View Filing |
| S-8 | 2025-08-21 | 2025-08-21 | View Filing |
| 8-K | 2025-08-21 | 2025-08-21 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-07-23 | 2025-07-23 | View Filing |
| ARS | 2025-07-16 | 2025-07-16 | View Filing |
| DEF 14A | 2025-07-16 | 2025-07-16 | View Filing |
| 10-K/A | 2025-07-16 | 2025-07-16 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 8-K | 2025-05-21 | 2025-05-21 | View Filing |
| 10-Q | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-08 | 2025-05-08 | View Filing |
| SC 13D | 2025-05-01 | 2025-05-01 | View Filing |
| 8-K | 2025-04-28 | 2025-04-28 | View Filing |
| 10-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-03 | 2025-03-03 | View Filing |
| 8-K | 2025-02-27 | 2025-02-27 | View Filing |
| SC 13G/A | 2025-02-13 | 2025-02-13 | View Filing |
| 8-K | 2025-02-11 | 2025-02-11 | View Filing |
| 4 | 2025-02-11 | 2025-02-11 | View Filing |
| 4 | 2025-02-11 | 2025-02-11 | View Filing |
| 4 | 2025-02-11 | 2025-02-11 | View Filing |
| 4 | 2025-02-11 | 2025-02-11 | View Filing |
| 8-K | 2025-01-22 | 2025-01-22 | View Filing |
| SC 13G | 2025-01-17 | 2025-01-17 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 8-K | 2025-01-03 | 2025-01-03 | View Filing |
| 8-K | 2024-12-17 | 2024-12-17 | View Filing |
| 4 | 2024-11-08 | 2024-11-08 | View Filing |
| 4 | 2024-11-08 | 2024-11-08 | View Filing |
| 4 | 2024-11-08 | 2024-11-08 | View Filing |
| 4 | 2024-11-08 | 2024-11-08 | View Filing |
| 10-Q | 2024-11-07 | 2024-11-07 | View Filing |
| 8-K | 2024-10-29 | 2024-10-29 | View Filing |
| 8-K | 2024-10-08 | 2024-10-08 | View Filing |
| 8-K | 2024-09-26 | 2024-09-26 | View Filing |
| 8-K | 2024-09-23 | 2024-09-23 | View Filing |
| SC 13G | 2024-09-16 | 2024-09-16 | View Filing |
| 10-Q | 2024-08-14 | 2024-08-14 | View Filing |
| 8-K | 2024-08-02 | 2024-08-02 | View Filing |
| 8-K | 2024-06-26 | 2024-06-26 | View Filing |
| 8-K | 2024-06-24 | 2024-06-24 | View Filing |
| 4 | 2024-06-21 | 2024-06-21 | View Filing |
| 3 | 2024-06-21 | 2024-06-21 | View Filing |
| ARS | 2024-06-20 | 2024-06-20 | View Filing |
| DEF 14A | 2024-06-20 | 2024-06-20 | View Filing |
| 8-K | 2024-06-10 | 2024-06-10 | View Filing |
| 4 | 2024-06-10 | 2024-06-10 | View Filing |
| 8-K | 2024-05-13 | 2024-05-10 | View Filing |
| 10-Q | 2024-05-09 | 2024-05-09 | View Filing |
| 8-K | 2024-05-06 | 2024-05-06 | View Filing |
| 4 | 2024-04-18 | 2024-04-18 | View Filing |
| 3 | 2024-04-02 | 2024-04-02 | View Filing |
| SC 13D | 2024-03-22 | 2024-03-22 | View Filing |
| 8-K | 2024-03-19 | 2024-03-19 | View Filing |
| 8-K | 2024-03-18 | 2024-03-18 | View Filing |
| 8-K | 2024-03-18 | 2024-03-18 | View Filing |
| 424B5 | 2024-03-18 | 2024-03-18 | View Filing |
| 10-K | 2024-03-06 | 2024-03-06 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Quantum Inspired Strategy | 17.54% | 0.98 | 18 | 0.48 | 0.45 | 14.68 |
| Bull Bias | 12.47% | 1.06 | 39 | 0.38 | 0.26 | 9.62 |
| Neural Forcast | 11.83% | 1.13 | 20 | 0.72 | 1.47 | 8.97 |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxx | xxxx | xxxx |
| xxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxxx | xxxx |
| xxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |